Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies
Authors:
- 26 March 2018
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 39 (02) , 155-171
Abstract
Lung transplantation has become an established therapeutic option for a variety of end-stage lung diseases. Technical advances in graft procurement, implantation, perioperative care, immunosuppression, and posttransplant medical management have led to significant improvements in 1-year survival, but outcomes after the first year have improved minimally over the last two decades. The main limitation to better long-term survival after lung transplantation is chronic lung allograft dysfunction (CLAD). CLAD also impairs quality of life and increases the costs of medical care. Our understanding of CLAD manifestations, risk factors, and mechanisms is rapidly evolving. Recognition of different CLAD phenotypes (e.g., bronchiolitis obliterans syndrome and restrictive allograft syndrome) and the unique pathogenic mechanisms will be important for developing novel therapies. In addition to alloimmune-mediated rejection, we now recognize the importance of alloimmune-independent mechanisms of injury to the allograft. CLAD is the consequence of dysregulated repair of allograft injury. Unfortunately, currently available therapies for CLAD are usually not effective. However, the advances in knowledge, reviewed in this manuscript, should lead to novel strategies for CLAD prevention and treatment, as well as improvement in long-term outcomes after lung transplantation. We provide an overview of the evolving terminology related to CLAD, its varying clinical phenotypes and their diagnosis, natural history, pathogenesis, and potential treatments.Keywords
This publication has 217 references indexed in Scilit:
- Revisiting the pathologic finding of diffuse alveolar damage after lung transplantationThe Journal of Heart and Lung Transplantation, 2012
- Thin-section Computed Tomography findings before and after azithromycin treatment of neutrophilic reversible lung allograft dysfunctionEuropean Radiology, 2011
- Five-year outcomes with alemtuzumab induction after lung transplantationThe Journal of Heart and Lung Transplantation, 2011
- Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allograftsThe Journal of Heart and Lung Transplantation, 2011
- Antibodies to Self-Antigens Predispose to Primary Lung Allograft Dysfunction and Chronic RejectionThe Annals of Thoracic Surgery, 2010
- Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantationThe Journal of Heart and Lung Transplantation, 2010
- Bronchoscopic Monitoring after Lung TransplantationSeminars in Respiratory and Critical Care Medicine, 2010
- Immunological Link Between Primary Graft Dysfunction and Chronic Lung Allograft RejectionThe Annals of Thoracic Surgery, 2008
- Upper Lobe Fibrosis: A Novel Manifestation of Chronic Allograft Dysfunction in Lung TransplantationThe Journal of Heart and Lung Transplantation, 2005
- Results of Single-Lung Transplantation for Bilateral Pulmonary FibrosisNew England Journal of Medicine, 1990